Cargando…
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders
OBJECTIVE: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine,...
Autores principales: | Fard, Ali Dehghani, Hosseini, Seyed Ahmad, Shahjahani, Mohammad, Salari, Fatemeh, Jaseb, Kaveh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913144/ https://www.ncbi.nlm.nih.gov/pubmed/24505535 |
Ejemplares similares
-
Evaluation of Signaling Pathways Involved in γ-Globin Gene Induction Using Fetal Hemoglobin Inducer Drugs
por: Rahim, Fakher, et al.
Publicado: (2013) -
The Role of microRNAs in Stemness of Cancer Stem Cells
por: Ali Hosseini Rad, Seyed Mohammad, et al.
Publicado: (2013) -
Prenatal Diagnosis of Different Polymorphisms of β-globin Gene in Ahvaz
por: Dehghanifard, Ali, et al.
Publicado: (2013) -
Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes
por: Steinberg, Martin H.
Publicado: (2020) -
BRAF Mutation in Hairy Cell Leukemia
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2014)